Mustang Bio, Inc. (NASDAQ:MBIO) has been assigned a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.33.
MBIO has been the topic of a number of recent research reports. BTIG Research started coverage on Mustang Bio in a research note on Monday, May 17th. They issued a “buy” rating and a $11.00 target price on the stock. Zacks Investment Research lowered Mustang Bio from a “buy” rating to a “hold” rating in a research note on Monday, April 12th.
MBIO stock traded down $0.04 on Friday, reaching $3.77. The company had a trading volume of 89,755 shares, compared to its average volume of 2,491,099. Mustang Bio has a 1 year low of $2.42 and a 1 year high of $5.22. The firm’s fifty day moving average price is $3.21. The company has a market capitalization of $329.17 million, a P/E ratio of -3.59 and a beta of 1.72.
Several institutional investors have recently modified their holdings of MBIO. Man Group plc purchased a new position in shares of Mustang Bio in the 1st quarter worth $223,000. AQR Capital Management LLC purchased a new position in shares of Mustang Bio in the 1st quarter worth $168,000. Ameriprise Financial Inc. raised its position in shares of Mustang Bio by 176.7% in the 1st quarter. Ameriprise Financial Inc. now owns 79,700 shares of the company’s stock worth $265,000 after buying an additional 50,900 shares during the period. Pinz Capital Management LP purchased a new position in shares of Mustang Bio in the 1st quarter worth $99,000. Finally, Nuveen Asset Management LLC raised its position in shares of Mustang Bio by 148.5% in the 1st quarter. Nuveen Asset Management LLC now owns 2,134,183 shares of the company’s stock worth $7,086,000 after buying an additional 1,275,507 shares during the period. 28.63% of the stock is currently owned by institutional investors.
Mustang Bio Company Profile
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Featured Story: What is cost of equity?
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.